Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cinryze Generic Name & Formulations
Legal Class
Rx
General Description
C1 esterase inhibitor (human) 500 Units/vial; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Pharmacological Class
C1 inhibitor.
How Supplied
Single-use vial—1
Manufacturer
Generic Availability
NO
Cinryze Indications
Indications
Routine prophylaxis against angioedema attacks in patients ≥6yrs with hereditary angioedema (HAE).
Cinryze Dosage and Administration
Adult
Give by IV infusion at a rate of 1mL/min (10mins). ≥12yrs: 1000 Units every 3–4 days. May consider doses up to 2500 Units (max 100 Units/kg) every 3–4 days if inadequate response.
Children
<6yrs: not established. Give by IV infusion at a rate of 1mL/min (5mins). 6–11yrs: 500 Units every 3–4 days. May adjust dose up to 1000 Units every 3–4 days based on response.
Cinryze Contraindications
Not Applicable
Cinryze Boxed Warnings
Not Applicable
Cinryze Warnings/Precautions
Warnings/Precautions
Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Have epinephrine available to treat hypersensitivity reactions. Monitor patients with known risk factors for thrombotic events. Pregnancy. Nursing mothers.
Cinryze Pharmacokinetics
See Literature
Cinryze Interactions
Not Applicable
Cinryze Adverse Reactions
Adverse Reactions
Headache, nausea, rash, vomiting, fever; thrombotic events, hypersensitivity reactions (may be severe; discontinue if occur).
Cinryze Clinical Trials
See Literature
Cinryze Note
Notes
To report infections that may have been transmitted by Cinryze, call CinryzeSolutions at (877) 945-1000.
Cinryze Patient Counseling
See Literature
